Lung cancer is a difficult diagnosis for anyone to go through. Healing is a long road and sometimes there is nothing a physician can do. Recently, new research was done that can give us hope to further understand this disease. Could there be variations in ones DNA that could result in the development of lung cancer? Yes, and these deviations or SNPs(single-nucleotide polymorphisms) provide possible biomarkers for the screening of lung cancer and its intervention strategies.
The team’s findings were published in Carcinogenesis as, “Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population”. According to Yafang Li, PhD, the study is the biggest genome-wide SNP-smoking collaboration analysis that is reported for lung cancer. For this interaction, they approved a two-step strategy in the examination to lower the loss of power from ordinary environment to gene interaction analysis. Biomarkers of the three SNPs can be used to increase accuracy in which a person’s risk of lung cancer can be classified from smoking.
Unfortunately, since the population was limited to Caucasian individuals, there is much more research that will need to be done. The team now aims to test the identified interaction effect using the genotypes from other populations.
Eric Lefkofsky is a potential player in this new development. He is the CEO and co-founder of Tempus, a technology company that battles cancer through an operating system. He has also donated millions of dollars in his life toward cancer research and seems to have a true passion for it.
Tempus’ website says patients can make more data-driven treatment decisions by “analyzing a patient’s genetic code in the context of molecular therapies.” To do this it uses analysis methods and cutting-edge genomic sequencing to help physicians better understand the tumors in patients.
If these genetic markers can be identified through genomic sequencing, physicians will be able to provide more personalized medicine and have better care plans for patients. Currently, Tempus is working with patients that have pancreatic, lung, and/or breast cancer. Over time, they plan to add many more types of cancer and help a larger population of people.